Achilles Therapeutics Q2 2024 Earnings Report

Achilles Therapeutics EPS Results

• Actual EPS: -$0.41
• Consensus EPS: -$0.41
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

Achilles Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Achilles Therapeutics Announcement Details

• Quarter: Q2 2024
• Date: 8/14/2024
• Time: TAS
• Conference Call Date: Wednesday, August 14, 2024
• Conference Call Time: 2:00AM ET

Achilles Therapeutics (NASDAQ:ACHL) is a clinical‐stage biotechnology company focused on the development of personalized T-cell immunotherapies targeting clonal neoantigens in patients with solid tumors. Headquartered in London, with additional research and development operations in Cambridge, Massachusetts, the company leverages its proprietary neoantigen discovery platform to identify and isolate tumor‐specific T cells that recognize mutations unique to each patient’s cancer. Achilles advances autologous T-cell products through manufacturing processes designed to enrich for high‐avidity, tumor-specific lymphocytes, which are then expanded and administered to patients in tailored cell therapy regimens.

The company’s pipeline encompasses several cell therapy candidates directed against neoantigens in non-small cell lung cancer, melanoma and bladder cancer. In preclinical studies and early‐phase clinical trials, Achilles has demonstrated the feasibility of its approach, showing durable T-cell persistence and evidence of tumor regression in select patients. By focusing on clonal neoantigens—mutations shared across all cancer cells within a patient—Achilles aims to deliver therapies with a high barrier to tumor escape and broad applicability across multiple cancer types.

Founded in 2016 as a spin-out from leading academic institutions, Achilles Therapeutics has established collaborations with major cancer research centers in Europe and the United States. The company’s dual presence on both sides of the Atlantic supports a seamless integration of translational research and clinical development. Historically, Achilles has secured funding from prominent life science investors and has forged strategic partnerships to accelerate the design and manufacture of its cell therapy products at scale.

Achilles is led by a management team with extensive experience in oncology drug development, cell therapy manufacturing and regulatory affairs. The executive leadership and board of directors include seasoned professionals who have held senior roles at global pharmaceutical and biotechnology organizations, underscoring the company’s commitment to bringing personalized immunotherapies to patients worldwide.